Nanobodies creating better medicines. Corporate presentation

Size: px
Start display at page:

Download "Nanobodies creating better medicines. Corporate presentation"

Transcription

1 Nanobodies creating better medicines Corporate presentation 27 August 2015

2 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. 2 2

3 Ablynx Corporate snapshot CORPORATE Drug discovery and development company in Ghent, Belgium 350 employees TECHNOLOGY Pioneer in next generation antibody-derived drugs Nanobodies Powerful proprietary drug discovery engine PRODUCTS >30 wholly-owned and partnered programmes across multiple indications Running 4 Phase II (RSV, RA, SLE); 1 Phase III (acquired TTP) to start in Q First potential product approval in 2018 PARTNERS AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck &Co., Merck Serono, Novartis and Taisho Pharmaceutical > 350M in cumulative cash received; > 7Bn in potential milestones plus royalties FINANCIALS 268M in cash at 30 June 2015 Quoted on Euronext (ABLX) and ADR on US OTC (ABYLY) 3

4 Unique technology Nanobodies pushing the limits of antibody technology

5 Nanobodies Derived from heavy-chain only antibodies Camelid heavy-chain only antibodies are stable and fully functional Nanobodies represent the next generation of antibody-derived biologics C H 1 V H V HH 12-15kDa V HH V L Ablynx s Nanobody C H 2 C L C H 2 small and robust easily linked together C H 3 C H 3 sequence homology comparable to humanised/human mabs nano- to picomolar affinities challenging and intractable targets Conventional antibodies Heavy chain only antibodies multiple administration routes manufacturing in microbial cells 5

6 6 Ablynx s drug discovery engine Rapid generation of high quality biologics Immunise llamas with antigen or use synthetic library Wide range of highly diverse Nanobodies with nM affinities Formatted Nanobodies ready for in vivo testing Cloning and production in microbial systems ~12-18 months

7 7 Ablynx s Nanobodies Competitive advantages Mix and match Targeting different pathways at once with a single Nanobody construct, e.g. multiple checkpoint inhibitors Challenging and intractable targets Nanobodies can reach conserved cryptic epitopes Nanobodies against ion channels and GPCRs Alternative delivery routes Inhalation Oral-to-topical Needle-free Ocular Cell- /tissue-homing Cell specificity Immune cell recruitment Tissue-specific targeting Customised half-life extension Fc Nanobodydrug conjugates High-yield, highconcentration, low-viscosity, microbial production Weeks/days/hours Cell killing Manufacturing Albuminbinding Nanobody Ag-1 Ag-1 Ag-2

8 Multi-specific Nanobodies Key capability in the development of highly potent and selective drugs

9 Multi-valent and multi-specific Nanobodies Proven capability and performance Ease of formatting and manufacture of multi-valent and multi-specifics allows rapid development of differentiating biologics Objective Binding Target(s) Result Increase potency/ affinity Block two pathways Tri-valent RSV F protein 7,000-fold increase vs monovalent Nanobody, superior to mab benchmark Bi-valent vwf 250-fold increase in affinity vs monovalent Nanobody Bi-specific CXCR4/CD4 160-fold increase versus mixture of monovalent Nanobodies and broader HIV strain coverage Bi-specific IL-17A/F block 2 cytokines at once for more effective blocking of immune response Increase selectivity Bi-specific EGFR/CEA more potent EGFR neutralisation on double positive tumour cells versus normal cells Bi-specific CD4/IL-12R selective binding and functional activity on CD4 + T cells Multiple commercial collaborations with focus on multi-specific Nanobodies Merck & Co., Inc.: immuno-oncology Boehringer Ingelheim: oncology; ocular Merck Serono: oncology; inflammation and osteo-arthritis 9

10 Immuno-oncology (I/O) Changing the cancer treatment paradigm Huge potential Proven substantial survival impact Commercial market for I/O drugs expected to grow to >$43bn by 2020* I/O drugs expected to treat 60% of cancers* Multiple targets Multiple approaches bearing fruit Increasing number of targets Combination therapies are the next generation Nanobodies Multi-specifics potentially increase efficacy and avoid escape mechanisms Ability to manufacture and deliver a combination drug in one Nanobody molecule Nature Reviews *BofA Merrill Lynch July

11 Immuno-oncology Significant collaboration with Merck & Co., Inc. Merck & Co., Inc. viewed as front runner in the field anti-pd-1 drug, Keytruda approved in US (Sept 2014) & EU (July 2015) for the treatment of advanced melanoma; generated sales of $55M in 2014 with sales estimated to amount to $560M in 2015 and $6Bn by 2020 advancing a broad and fast-growing clinical development program for Keytruda with more than 85 clinical trials across more than 30 tumor types and more than 14,000 patients Collaboration with Merck & Co., Inc. signed Feb 14 and expanded in July 15 up to 17 programmes with focus on multi-specific combinations targeting immunecheckpoint inhibitors 33M upfront received; potentially up to 5.7bn in future milestones plus royalties *Leerink August

12 Product pipeline >30 active wholly-owned and partnered programmes

13 FULLY OWNED PARTNERED 13 Products in development Multiple shots on goal Therapeutic area Product name Target Discovery Pre-clinical Phase I Phase II Phase III Filing Clinically validated targets First-in-class Haematology Respiratory caplacizumab ALX-0171 vwf RSV Oncology/ Immuno-oncology Various Inflammation/ Immunology Various Ocular Various Other Various Inflammation/ Immunology ALX-0061 ALX-0761 ozoralizumab IL-6R IL-17F/IL-17A TNFα Greater China Japan Various Oncology/ Immuno-oncology Various Bone disorders ALX-0141 RANKL Greater China Neurology Various CXCR2 Other Various

14 Clinical pipeline Key value drivers PROPRIETARY Programme (target) Indication Key differentiating features Stage Caplacizumab (vwf) Thrombotic thrombocytopenic purpura First-in-class orphan drug Novel mode of action Inhibition of micro-clot formation Start Phase III Q and MAA filing in H in EU for conditional approval ALX-0171 (RSV) Respiratory syncytial virus infection First-in-class addressing high unmet need Inhaled Nanobody delivered to infection site Highly potent trivalent construct First-in-infant study on-going: results expected in H PARTNERED Programme (target) Indication Key differentiating features Stage Partner ALX-0061 (IL-6R) RA, SLE Best-in-class opportunity Monovalent interaction; strong affinity and preferential binding to soluble IL-6R 3 Phase II studies (RA; SLE) on-going; RA results expected in H

15 15 Caplacizumab Wholly-owned anti-vwf Nanobody First-in-class bivalent Nanobody with Orphan Drug Status Developed to treat acquired thrombotic thrombocytopenic purpura (TTP) Filing expected in H for conditional approval in Europe based on Phase II results Phase III study to start in Q to support BLA submission in USA Ablynx committed to lead commercialisation in Europe and USA Peak sales potential of 300M- 400M 1 1 US, EU, Japan, other markets (Brazil, Canada, Russia, Mexico, Australia)

16 16 Thrombotic thrombocytopenic purpura (TTP) Life-threatening acute blood clotting disorder episode diagnosis treatment TTP patient Emergency Room ICU/haematology unit Acute onset in otherwise healthy person Initial diagnosis based on thrombocytopenia & haemolysis Plasma exchange initiation Haematologist Key decision maker Extensive microscopic clots formed in small blood vessels throughout the body Ultra-rare disease incidence of ~11/million 1 (acquired TTP - 90%; congenital TTP - 10%) ~10,000 acute events annually in US and Europe High unmet medical need no therapeutic drug approved for this indication mortality remains high (10-30%) 2 and ~ 36% of patients relapse 1 major morbidities after TTP episode such as neurocognitive impairment current standard of care: plasma exchange (PE) plus immune suppressants 1 George et al, 2008; 2 Allford et al, 2003, Kremer Hovinga, 2010; Benhamou 2012

17 17 Caplacizumab mode of action Stops formation of micro-clots Caplacizumab blocks the platelet ULvWF interaction Ultra-Large (UL) vwf multimers endothelium ADAMTS13 activity is impaired Platelet string formation in patients with TTP Caplacizumab binds to A1 domain of vwf and thereby inhibits platelet string formation Ex vivo assay for platelet string formation Fluorescence microscopy image of platelets adhering to UL-vWF in plasma of TTP patients ULvWF Without treatment, fluorescently labelled platelets adhere to UL-vWF, observed as string-like structures ULvWF and anti-vwf Nanobody Caplacizumab inhibits the formation of platelet strings and potentially the associated microvascular thrombi in many organs

18 RANDOMISATION 18 Caplacizumab proven clinical benefit Strong clinical proof-of-concept in TITAN Phase II study Study design Study results PE Placebo N=39 30 days 30 days Time to platelet normalisation Median days (95% CI) No prior PE Caplacizumab 3.0 (2.7, 3.9) N = 34 Placebo 4.9 (3.2, 6.6) N = 35 1:1 Median days (95% CI) One prior PE 2.4 (1.9, 3.0) N = (2.9, 5.7) N = 4 PE 30 days 30 days Number of subjects Caplacizumab Placebo 75 subjects Caplacizumab N=36 Subjects with exacerbation within 30 days after stopping PE 3 (8%) 11 (28%) Primary endpoint: time to confirmed normalisation of platelet count Secondary endpoints: exacerbations; relapses; PE parameters; mortality; major clinical events Deaths 0 2 Primary endpoint met (p=0.005) 40% reduction in time to platelet normalisation 71% fewer patients with exacerbations Filing for conditional approval in Europe in 2017 based on TITAN results

19 RANDOMISATION 19 Caplacizumab Phase III study Double-blind placebo controlled study (Q to Q4 2017) Primary endpoint: time to confirmed normalisation of platelet count Exacerbation restart daily PE and open label caplacizumab 1:1 30 days Daily PE Placebo* N=46 TREATMENT PERIOD** * iv bolus (10mg) followed by daily sc (10mg) ** incl. corticosteroids at start of daily PE until underlying disease activity resolved FOLLOW-UP PERIOD (4 weeks) Daily PE 30 days 92 subjects Caplacizumab* N=46 Potential extension of blinded study drug if relapse, restart daily PE and open label caplacizumab Secondary endpoints: exacerbations/relapses; mortality rate; severe morbidity; organ damage biomarkers (troponin, creatinine, LDH); PE parameters; days in ICU/hospital; AEs; PD; PK; immunogenicity

20 Caplacizumab commercial strategy Ablynx to retain 100% ownership in Europe and USA Strategic opportunity to develop into a commercial stage company targets an ultra rare indication with high unmet medical need clear benefit demonstrated in the clinic strong support from medical community established KOL network modest commercial infrastructure requirements Filing for conditional approval in Europe in H Phase III on track to start in Q to support BLA submission in USA in 2018 Development of patient registries underway Caplacizumab could be approved for sale in Europe in

21 21 ALX-0171 Wholly-owned anti-rsv Nanobody First-in-class trivalent Nanobody Developed for the treatment of respiratory syncytial virus (RSV) infection in infants Delivered by inhalation First-in-infant Phase IIa on-going with results expected in H Opportunity in multi-billion dollar market

22 22 RSV infection in infants High unmet medical need Leading cause of infant hospitalisation and primary viral cause of infant death ~65% of infants are infected in their first year of life ~300,000 children* (< 5 years) hospitalised per year in 7 major markets 1,2 ~2.1 million outpatient visits annually in the USA among children <5 years of age increased medical cost in the first year following RSV infection 3 prolonged wheezing and increased risk of asthma development 4 No current treatment options available Synagis used as prophylaxis in high-risk pre-term infants only ($900M sales in 2014) Evolves to distressing symptoms Symptomatic treatment including inhaled corticosteroids & bronchodilator 8-20% hospitalised * Extrapolation based on estimated US prevalence 1 Hall et al, NEJM, 2009; 2 Lee et al, Human Vaccines, 2005; 3 Shi et al, J Med Econ, 2011; 4 Sigurs et al, Thorax, 2010; Backman et al, Acta Pediatr, 2014

23 % of lambs with score 1 Mean % lung tissue with viral lesions 23 ALX-0171 Key milestones achieved Well tolerated in multiple Phase I clinical studies in adults Strong in vitro and in vivo study results potent anti-viral effect against recent clinical RSV isolates 10,000 fold reduction in viral titres and superiority in vitro compared with palivizumab (Synagis ) 1 daily inhalation of ALX-0171 for 3 consecutive days in neonatal lamb model for infant RSV demonstrated markedly reduced signs and symptoms of illness ( Malaise Score ) 2 and viral lesions 100 Malaise score 60 Lung viral lesions (day 6 post infection) 80 Control ALX Control ALX-0171 RSV infection Treatment ALX-0171 or formulation buffer 1 Vaccines of the World (Oct 2013) 2 RSV Symposium (Nov 2014) presentations on

24 RANDOMISATION ALX-0171 First-in-infant inhalation study on-going Infants aged 3 to <24 months who are hospitalised for RSV infection Study centres in Europe and Asia-Pacific region Custom-developed infant inhalation device (vibrating mesh) ALX-0171 N=20 Open-label lead-in N=5 Review by DMC* 2:1 Inhaled ALX-0171 once/day or placebo 3 consecutive days Inhaled ALX-0171 once/day 3 consecutive days Placebo N=10 Primary endpoint: Safety and tolerability of ALX-0171 Started Q Results expected H Secondary endpoints: Clinical effect (feeding, respiratory rate, wheezing, coughing, general appearance) PD (viral load), PK (ALX-0171 systemic concentration) and immunogenicity * Data Monitoring Committee 24

25 ALX-0171 Significant progress today and next steps Strong therapeutic effect demonstrated in a relevant neonatal animal model for infant RSV infection Well tolerated in multiple Phase I studies in adults First-in-infant Phase IIa study on-going with results expected in H Worldwide Phase IIb infant study planned to start in 2016 Potential POC for an inhaled Nanobody 25 25

26 ALX-0061 Anti-IL-6R Nanobody partnered with AbbVie Monovalent half-life extended Nanobody Best-in-class potential for the treatment of auto-immune disorders Global licensing agreement with AbbVie 2 Phase IIb studies in RA and Phase II study in SLE on-going Opportunity in multi-billion dollar markets RA: rheumatoid arthritis SLE: systemic lupus erythematosus 26

27 % of patients ALX-0061 Compelling Phase IIa results in RA patients 100 ACR50 score as potential differentiating factor All unmodified ALX-0061 at week 24 (N=24) ACR20 ACR50 ACR70 DAS28 remission Boolean remission Data published 13 February 2013: press release available on Ablynx s website 27

28 ALX-0061 Global licensing deal with AbbVie Economics $175M upfront at signing in September 2013 $665M total potential milestones plus double-digit royalties Ablynx Perform and fund Phase I study with subcutaneous formulation (successfully completed in 2014) Perform and fund Phase II studies in RA and SLE (on-going) AbbVie Pay a fee for each indication if they exercise the right to license ALX-0061 after completion of the Phase II studies Responsible for Phase III development and registration Commercialisation AbbVie is responsible for global commercialisation Ablynx retains option to co-promote ALX-0061 in the Benelux 28 28

29 RANDOMISATION ALX-0061 Phase IIb RA combination study with MTX* First patient dosed in March 2015 Adult subjects with moderate to severe RA despite MTX therapy Worldwide, randomised, double-blind, placebo-controlled 24 week dose finding study Eligible subjects will be invited to roll-over into open-label extension (OLE) study ALX-0061 dose 1, Q4W Primary endpoint at week 12: ACR20 response 330 subjects 1:1:1:1:1 ALX-0061 dose 2, Q4W ALX-0061 dose 2, Q2W ALX-0061 dose 3, Q2W Placebo Secondary endpoints: ACR responses over time, disease activity scores, EULAR DAS28 response, remission, effects on quality of life Other assessments: pharmacokinetics, pharmacodynamics, safety/tolerability, immunogenicity * methotrexate 29

30 RANDOMISATION 30 ALX-0061 Phase IIb RA monotherapy study First patient dosed in April 2015 Adult subjects with moderate to severe RA who are intolerant to MTX or for whom continued MTX is inappropriate Worldwide, randomised, double-blind 12 week study (Ro)Actemra arm to obtain parallel descriptive information on efficacy and safety Eligible ALX-0061 treated subjects will be invited to roll-over into an OLE study ALX-0061 dose 1, Q4W Primary endpoint at week 12: ACR20 response 1:1:1:1 ALX-0061 dose 1, Q2W ALX-0061 dose 2, Q2W Secondary endpoints: ACR responses over time, disease activity scores, EULAR DAS28 response, remission, effects on quality of life 228 subjects (Ro)Actemra 162mg Q1W (EU) or Q2W (US) Other assessments: pharmacokinetics, pharmacodynamics, safety/tolerability, immunogenicity

31 RANDOMISATION 31 ALX-0061 Phase II study in SLE First patient dosed in August 2015 Adult subjects with moderate to severe active, seropositive SLE despite standard of care Worldwide, randomised, double-blind, placebo-controlled 48 week dose-range finding study ALX-0061 dose 1, Q4W Primary endpoint at week 24: mbicla 1 response ~300 subjects 1:1:1:1:1 ALX-0061 dose 2, Q4W ALX-0061 dose 2, Q2W ALX-0061 dose 3, Q2W Placebo Secondary endpoints: (m)bicla, (m)sri 2, (m)sledai 3-2K and BILAG over time; patient s and physician s global assessment; flare rate; corticosteroid reduction Other assessments: pharmacokinetics, pharmacodynamics, safety/tolerability, immunogenicity 1 modified BILAG-based Combined Lupus Assessment 2 modified SLE responder index 3 modified SLE disease activity index 2000

32 ALX-0061 Key data points in clinical development Phase I sc study Results announced 23 Oct 2014 ALX-0061 showed >80% bioavailability after sc injection Phase IIb combination and monotherapy studies in RA Top line results potentially continues development in RA Phase II RA OLE study Phase II study in SLE Top line results potentially continues development in SLE 32

33 33 Additional clinical assets Licensed to partners ALX-0761 anti-il-17a/f Merck Serono (global) ALX-0141 anti-rankl Eddingpharm (Greater China) Ozoralizumab anti-tnfα Eddingpharm (Greater China) Ozoralizumab anti-tnfα Taisho Pharmaceutical (Japan)

34 Partnerships Broad platform exploitation and cash generation

35 35 Current partnerships Broad platform exploitation and value creation Global licensing deal for ALX-0061 (anti-il-6r) in RA and SLE Immuno-onco deal (up to 17 programmes) with focus on multi-specifics; Ion channel deal Strategic discovery alliance (focus on bi-specifics) 8 programmes on-going 6 programmes on-going (lead project in Phase Ib) Two licensing deals in Greater China (ALX-0141 and ozoralizumab) Licensing deal in Japan for ozoralizumab in RA Target-based discovery deal Research collaboration in multiple sclerosis >25 active programmes; > 350M in non-dilutive cash received ~ 7Bn in potential future milestones plus royalties

36 Outlook Potential value enhancing events

37 2015 objectives Maximising stakeholder value Developing the pipeline Programme read outs Commercial Caplacizumab (vwf): i) confirm regulatory pathway ii) start Ph III in acquired TTP ALX-0061 (IL-6R): dose first patient in: i) Ph IIb RA combination therapy ii) Ph IIb RA monotherapy iii) Ph II in SLE ALX-0171 (RSV): complete recruitment of Phase IIa Partnered programmes advancing ALX-0761 (IL-17A/F) (Merck Serono): study completion by end 2015 Potential in vivo pre-clinical POC results from initial programmes as part of IO collaboration with Merck & Co Caplacizumab (vwf): determine partnering and commercialisation strategy Potential milestone payments from on-going partnerships Continuing partnering discussions Extend existing collaborations/ enter into new collaborations 37 37

38 38 Long term value creation Potential clinical and regulatory key events Clinical study results Key regulatory events 2015 ALX-0761 Phase Ib POC (psoriasis) Licensed to Merck Serono (worldwide) 2016 ALX-0171 Infant Phase IIa (RSV) Wholly-owned ALX-0061 Phase IIb combination therapy (RA) AbbVie have option to license worldwide ALX-0061 Phase IIb monotherapy (RA) AbbVie have option to license worldwide 2017 Caplacizumab MAA filing EU Phase III results (TTP) Wholly-owned ALX-0171 Infant Phase IIb (RSV) Wholly-owned ALX-0141 and ozoralizumab Phase I/II in China Licensed to Eddingpharm (China) ALX-0761 Phase IIa (psoriasis) Licensed to Merck Serono (worldwide) 2018 Caplacizumab conditional approval EU and BLA filing in US Wholly-owned ALX-0061 Phase II (SLE) AbbVie have option to license worldwide Results from various patient studies with partners

39 Questions CONTACT DETAILS Investor Relations ablynx.com

Nanobodies creating better medicines. Corporate presentation

Nanobodies creating better medicines. Corporate presentation Nanobodies creating better medicines Corporate presentation November 2015 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the

More information

Nanobodies creating better medicines. Investor presentation

Nanobodies creating better medicines. Investor presentation Nanobodies creating better medicines Investor presentation February 2016 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the

More information

Nanobodies creating better medicines. Corporate presentation

Nanobodies creating better medicines. Corporate presentation Nanobodies creating better medicines Corporate presentation May 2015 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company

More information

ABLYNX AT A GLANCE Nanobodies, a novel class of antibody- derived therapeutic proteins wholly-owned clinical development stage 250 people

ABLYNX AT A GLANCE Nanobodies, a novel class of antibody- derived therapeutic proteins wholly-owned clinical development stage 250 people ANNUAL REPORT ABLYNX AT A GLANCE Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of antibodyderived therapeutic proteins based on single-domain

More information

TAKE A LOOK AT OUR 3D-PRINTED GRAPHS 2015 ANNUAL REPORT

TAKE A LOOK AT OUR 3D-PRINTED GRAPHS 2015 ANNUAL REPORT TAKE A LOOK AT OUR 3D-PRINTED GRAPHS 2015 ANNUAL REPORT INDEX CORPORATE OVERVIEW 5 1. INTRODUCTION 7 Ablynx at a glance 9 2015 achievements 10 Letter to our stakeholders 12 Company strategy and outlook

More information

The need for a Biobank @ Ablynx

The need for a Biobank @ Ablynx The need for a Biobank @ Ablynx Dr. Dominique Vlieghe, Section Head Information Management, Ablynx Nanobodies - Inspired by nature Forward looking statements Certain statements, beliefs and opinions in

More information

Week 12 study results

Week 12 study results Week 12 study results 15 April 2015 Copyright 2015 Galapagos NV Disclaimer This document may contain certain statements, including forward-looking statements, such as statements concerning the safety and

More information

Additional Data from the TITAN Trial with the Anti-vWF Nanobody Caplacizumab in the Treatment of Acquired TTP

Additional Data from the TITAN Trial with the Anti-vWF Nanobody Caplacizumab in the Treatment of Acquired TTP Additional Data from the TITAN Trial with the Anti-vWF Nanobody Caplacizumab in the Treatment of Acquired TTP ISTH, Toronto, June 24 th 2015 Flora Peyvandi, Marie Scully, Paul Knöbl, Johanna A. Kremer

More information

The predictive value of ADAMTS13 activity for treatment monitoring of patients with acquired TTP: data from the Phase II TITAN trial with caplacizumab

The predictive value of ADAMTS13 activity for treatment monitoring of patients with acquired TTP: data from the Phase II TITAN trial with caplacizumab The predictive value of ADAMTS13 activity for treatment monitoring of patients with acquired TTP: data from the Phase II TITAN trial with caplacizumab ISTH, Toronto, June 24 th 2015 Filip Callewaert, Hans

More information

Mid-Clinical Stage Antiviral Drug Development Company

Mid-Clinical Stage Antiviral Drug Development Company BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au

More information

Nanobodies creating better medicines. Investor presentation

Nanobodies creating better medicines. Investor presentation Nanobodies creating better medicines Investor presentation June 2016 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company

More information

Company Update. March 2011

Company Update. March 2011 Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various

More information

Nanobodies. inspired by nature

Nanobodies. inspired by nature Nanobodies inspired by nature ANNUAL REPORT 2010 Content 01 Introduction 02 03 Letter to the Shareholders 05 Highlights 2010 02 The Nanobody product engine 06 07 Products in the clinic 17 Pre-clinical

More information

JAK1 and beyond. Investor Presentation February 2013. Copyright 2013 Galapagos NV

JAK1 and beyond. Investor Presentation February 2013. Copyright 2013 Galapagos NV JAK1 and beyond Investor Presentation February 2013 Copyright 2013 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

JAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV

JAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV JAK1 and beyond Investor Presentation January 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.

More information

Biotest Group. H1 2014 Conference call 12 August 2014

Biotest Group. H1 2014 Conference call 12 August 2014 Biotest Group H1 2014 Conference call 12 August 2014 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced

More information

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014 Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will

More information

A career on the science park

A career on the science park A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

Dec. 9, 2013, 11:00 a.m. EST

Dec. 9, 2013, 11:00 a.m. EST Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)

More information

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma 12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

Monoclonal antibody (mab) products are currently a fast

Monoclonal antibody (mab) products are currently a fast Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

August 28, 2012. Company Update Commerzbank Sector Conference Week

August 28, 2012. Company Update Commerzbank Sector Conference Week August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

(the "Company") CANCELLATION OF PREFERENTIAL SUBSCRIPTION RIGHTS OF EXISTING SHAREHOLDERS

(the Company) CANCELLATION OF PREFERENTIAL SUBSCRIPTION RIGHTS OF EXISTING SHAREHOLDERS Unofficial translation of a Dutch original ABLYNX NV Public Limited Liability Company (Naamloze Vennootschap) Registered offices: Technologiepark 21, 9052 Zwijnaarde Enterprise number: 0475.295.446 (the

More information

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010

Rodman & Renshaw Annual Global Investment Conference. September 13, 2010 Rodman & Renshaw Annual Global Investment Conference September 13, 2010 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA VERTEX PHARMACEUTICALS INC / MA FORM 8-K (Unscheduled Material Events) Filed 6/1/2005 For Period Ending 5/31/2005 Address 130 WAVERLY STREET CAMBRIDGE, Massachusetts 02139-4242 Telephone 616-577-6000 CIK

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment

More information

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

Medical Therapies Limited EGM Presentation

Medical Therapies Limited EGM Presentation Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for

More information

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its

More information

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines

More information

Eigenkapitalforum 2013. Company Update November 12, 2013

Eigenkapitalforum 2013. Company Update November 12, 2013 Eigenkapitalforum 2013 Company Update November 12, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation

More information

Company Overview March 2015

Company Overview March 2015 Company Overview March 2015 Disclaimer This presentation may contain forward-looking statements, including, without limitation, statements containing the words believes, expects, plans, estimates and similar

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? PD Dr. med. Thomas Sudhop Bundesinstitut für Arzneimittel, Bonn Bundesinstitut für Arzneimittel IMP

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

Q3 2015 Conference Call

Q3 2015 Conference Call November 4, 2015 Q3 2015 Conference Call 1 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements

More information

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

Corporate Booklet February 2016

Corporate Booklet February 2016 Corporate Booklet February 2016 Certain statements contained herein including, but not limited to, expected licensing transactions, statements related to anticipated timing of initiation and completion

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

Jefferies 2012 Global Healthcare Conference. June 8, 2012

Jefferies 2012 Global Healthcare Conference. June 8, 2012 Jefferies 2012 Global Healthcare Conference June 8, 2012 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

Investor science conference call: American College of Rheumatology 2015. San Francisco, California, USA 11 November 2015

Investor science conference call: American College of Rheumatology 2015. San Francisco, California, USA 11 November 2015 Investor science conference call: American College of Rheumatology 2015 San Francisco, California, USA 11 November 2015 Forward-looking statements In order, among otherthings, to utilise the 'safe harbour'provisions

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

EMA and Progressive Multifocal Leukoencephalopathy.

EMA and Progressive Multifocal Leukoencephalopathy. EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011 Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D. The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma

Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.

More information

Nucala. (mepolizumab) New Product Slideshow

Nucala. (mepolizumab) New Product Slideshow Nucala (mepolizumab) New Product Slideshow Introduction Brand name: Nucala Generic name: Mepolizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg per vial; lyophilized

More information

UPDATED INVESTOR PRESENTATION June 2015

UPDATED INVESTOR PRESENTATION June 2015 UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional

More information

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 1 Timo Veromaa President & CEO 2 Company Highlights 2014 through Q1 2015 Continued advances

More information

Developing Innovative Therapeutics for People with Orphan Liver Disease

Developing Innovative Therapeutics for People with Orphan Liver Disease Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015 Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation May 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Biotest AG Welcome to our Analysts conference

Biotest AG Welcome to our Analysts conference Biotest AG Welcome to our Analysts conference 0 Agenda Plasma proteins Biotherapeutics Diagnostics Key Financials 1 Biotest at a glance Further growth by woldwide sales Sales Q1-Q3 2008: 323.0 m Full year

More information

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell

More information

Cancer, Autoimmune & Other Serious Diseases

Cancer, Autoimmune & Other Serious Diseases Focused on Therapy: Cancer, Autoimmune & Other Serious Diseases 2012 Wedbush PacGrow Life Sciences Conference Gerard Gorman, SVP Finance and CFO It s all about Life Good afternoon. I m Gerard Gorman. Thank

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Clinical trials preclinical requirements. Clinical trials - legislation

Clinical trials preclinical requirements. Clinical trials - legislation Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive

More information

Foundational Issues Related to Immunotherapy and Melanoma

Foundational Issues Related to Immunotherapy and Melanoma Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information